Abakkus Flexi Cap Fund opens a position in Zydus Lifesciences as June-quarter profit falls 35% to ₹940 crore: is the stock at ₹1,135 and 23 times earnings a buy?

Abakkus Flexi Cap Fund opened a new position in Zydus Lifesciences in September, according to news reports of the fund's monthly portfolio. The fund bought into a company whose June-quarter profit fell 35% even though its sales grew 22%. At ₹1,135 the stock trades at about 23 times earnings. Is that a bargain after the fall, or a sign the profit squeeze is not over?

Zydus Lifesciences (NSE: ZYDUSLIFE, BSE: 532321) - Share price: ₹1,135 (screener.in, 23 October 2026, previous close) - Market cap: ₹1,13,217 crore - P/E: about 23 (Sun Pharma about 33, Cipla about 30, Dr Reddy's about 32) - 52-week range: ₹836 to ₹1,232 (the price is 8% below the high and 36% above the low) - Listed on the NSE and BSE mainboard for many years, so this is not a recent IPO

What the fund did, and what is not known

Abakkus Flexi Cap Fund is a mutual fund from Abakkus, the fund house co-founded by Sunil Singhania. The fund itself was launched in December 2025 and is run by fund manager Sanjay Doshi. Its reported size at the end of September 2026 was ₹7,843.87 crore.

Mutual funds publish their holdings once a month. News reports on the September 2026 portfolio (The Economic Times, using ACE MF data, and 5paisa) say the fund:

- opened a new position in Zydus Lifesciences, and - exited Cyient DLM.

The reports do not give the number of Zydus shares, the amount invested or the price paid. This is news-based. For the exact figures, read the fund's September portfolio on the Abakkus Mutual Fund website or the AMFI site. Another fund, ICICI Prudential Flexi Cap, exited Zydus in June 2026. Different funds have different goals and timing, so this does not settle the question either way.

What Zydus does

Zydus Lifesciences, formerly Cadila Healthcare, traces its roots to 1952 and is controlled by the Patel family (promoter holding 75.01%). It sells medicines in India and abroad, and also makes consumer products. In the June 2026 quarter, sales came from:

- North America generics and specialty medicines: 40% - India branded medicines: 23% - Consumer wellness (Complan, Glucon-D, Nutralite, Everyuth): 18% - International markets: 12% - MedTech and active ingredients: about 6% (the shares are rounded, so they add to about 99%)

June 2026 quarter: sales up 22%, profit down 35%

- Revenue: ₹8,017 crore, up 22% from ₹6,574 crore. - EBITDA: ₹1,929 crore, down 7.6%. The margin fell from 31.8% to 24.1%. - Net profit attributable to owners: ₹940 crore, down 35.9% from ₹1,467 crore. (The data site's consolidated figure of ₹990 crore includes the minority share.) - Research spend: ₹642 crore, 8% of revenue. - Net debt: ₹5,904 crore at 30 June 2026 (borrowings minus cash), against a net cash position a year ago.

Why did profit fall? Management's presentation points to heavier research spending, costs from the Assertio acquisition (a US specialty medicine company) and the launch of its first US biosimilar, and higher interest on the new debt. It did not give a date for margins to recover.

Business Share of sales Growth over a year Note ------------ North America 40% -2.6% in rupees (US dollar sales -12% to $327 million) Price pressure in US generics India formulations 23% +19.5% Beat the market in most medicine groups Consumer wellness 18% +67.2% Includes the CCL acquisition International markets 12% +34% Emerging markets and Europe

Three years of numbers

Year to March Revenue (₹ crore) Operating margin Net profit (₹ crore) Cash from operations (₹ crore) Borrowings (₹ crore) ------------------ FY23 17,237 22% 2,092 2,689 1,195 FY24 19,547 28% 3,973 3,228 804 FY25 23,242 30% 4,673 6,781 3,213 FY26 27,148 31% 5,124 2,117 12,496

Consolidated. Source: company results via screener.in.

Two things stand out in FY26.

Cash did not follow profit. Cash from operations was ₹2,117 crore against ₹5,124 crore of profit, about 41%. Free cash flow (operating cash less spending on plants and equipment) was about -₹530 crore. FY25 was the opposite, with ₹6,781 crore. The reason for the FY26 gap was not checked in this note; a large acquisition year usually brings extra working capital, but that is an assumption.

Debt rose almost four times. Borrowings went from ₹3,213 crore to ₹12,496 crore, and fixed assets from ₹13,134 crore to ₹24,106 crore, in the period of its acquisitions. Borrowings are the total owed at 31 March 2026. Net debt (borrowings minus cash) was ₹5,904 crore at 30 June 2026, so the two figures are not the same measure. The interest bill is now about ₹156 crore a quarter, against ₹85 crore a year earlier.

How the valuation compares

Company P/E Market cap (₹ crore) Latest quarter profit change ------------ Zydus 23.2 1,13,217 -35% Cipla 30.0 1,07,520 -39% Dr Reddy's 32.1 1,03,417 -69% Sun Pharma 33.4 4,21,803 +6% Torrent 78.7 1,75,551 +6% Divi's Labs 81.6 2,43,222 +66%

Source: screener.in, 23 October 2026. These peers are my own pick of large listed drug makers; the company does not name them.

Zydus is the cheapest of the group on P/E. But the P/E uses the last four quarters of profit, and the latest quarter is much lower than the one it replaced. Cipla and Dr Reddy's also posted falling profits this quarter, so the lower multiples across much of the group reflect weaker earnings, not just a bargain.

Who owns the stock

Quarter Promoters Foreign investors Domestic funds Public --------------- Dec 2024 74.98% 7.53% 10.61% 6.85% Jun 2025 75.00% 7.13% 11.09% 6.74% Dec 2025 75.00% 7.06% 11.08% 6.86% Jun 2026 75.02% 6.89% 11.27% 6.83% Sep 2026 75.01% 7.05% 11.28% 6.66%

Ownership has barely moved in two years. Share capital is unchanged at ₹101 crore, so there was no big share issue.

Latest news

On 21 October 2026 Zydus said the US drug regulator (USFDA) approved its generic menopause patch (estradiol and levonorgestrel), with 180 days of exclusive sale rights, subject to the regulator's conditions. The US market for the product was about $45.7 million a year. The group now has 458 USFDA approvals from 516 applications filed.

Management's plans, in its own words

These are management's forward-looking statements, not facts.

- The first US biosimilar, NUFYMCO (ranibizumab injection), launched in the June quarter. - The USFDA gave priority review to saroglitazar for primary biliary cholangitis (PBC). If approved, it would be the company's first new chemical drug approved in the US (the company's own description). - The injectable plant at Zydus Biotech Park was cleared after a USFDA inspection. - A joint venture in Sri Lanka to make medicines locally. - Phase III trials in India for a second biosimilar; the WHO accepted the dossier for a measles-rubella vaccine. - Capital spending was ₹585 crore in the quarter, against ₹402 crore a year earlier. - No numeric guidance for FY27 was given in the Q1 presentation and no date was given for the margin to recover.

Risks to watch

- Margin squeeze. The EBITDA margin fell 7.7 percentage points in a year, with no recovery date. - US price pressure. Dollar sales in North America fell 12%. - Higher debt. Net debt to EBITDA was 0.70 times, against net cash a year ago. - Weak cash conversion in FY26. - Currency. Costs paid in dollars (imported ingredients, research) rise when the rupee weakens, though dollar sales gain.

Key point: A fund buying into Zydus tells you someone with a full portfolio view finds the stock interesting. It does not tell you the price paid or whether the margin squeeze is over.

Should you buy because a fund did?

A fund's purchase is one input, not a reason. For Zydus, what to look for next: the September-quarter results due on 4 November 2026, whether the operating margin returns above 30%, and whether the debt starts falling. Check the fund's own portfolio file for the real share count and size of the holding.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- https://www.5paisa.com/blog/abakkus-flexi-cap-fund-raises-holdings-in-35-stocks-during-september-2026 - https://www.inkl.com/news/sunil-singhania-backed-abakkus-flexi-cap-fund-increases-stake-in-ril-hdfc-bank-groww-and-32-others-in-september (The Economic Times, 16 October 2026) - https://askfuzz.ai/discover/news/mutual-funds/flexi-cap-funds-reshuffle-portfolios-in-june-2026 - https://www.personalfn.com/factsheet/abakkus-flexi-cap-fund-reg-g- - https://choiceindia.com/mutual-funds/abakkus-flexi-cap-fund-growth - Company filings on the NSE and BSE: Q1 FY27 investor presentation and results (11 August 2026) and press release (21 October 2026)